NCT07245147Not yet recruiting
REDO-AF: Randomized Evaluation of Dual Options for AF Re-intervention
Source: ClinicalTrials.gov · Last updated 24 Nov 2025
Brief summary (registry, in English)
The goal of this randomized open-label clinical trial is to evaluate two different strategies for the treatment of recurrent atrial fibrillation (AF) after AF ablation. Patients who have symptomatic, drug-refractory recurrence of AF will be randomized to either a redo AF ablation vs conduction system pacing with AV node ablation. Patients will need to have undergone at least 1 prior AF ablation to be considered eligible for the study. The current trial is a vanguard study of 16 patients and will determine the feasibility of enrolment, compare changes in quality of life, and inform the design of the definitive REDO AF trial.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 1 Nov 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Jacqueline Joza
- Diseases
- Atrial fibrillation
- NCT number
- NCT07245147
What you commit to
- Study type: Interventional
- Planned participants: 16
- From 1 Nov 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Myocardial infarction, stroke, or coronary revascularization within the previous 3 months
Other illness
- Severe valvular disease defined by echo criteria
Lab values
- LVEF \<40% or need for an ICD
Other
- Life expectancy \<24 months
- Lack of capacity to consent
Who the study is looking for
- One or more prior left atrial (LA) ablation procedure(s) for AF
- Symptomatic AF/atypical atrial flutter/atrial tachycardia with failure of or intolerance to medical rate or rhythm control therapy, that is detected at \>2 months post most recent LA ablation procedure
- Either a LA volume index on any prior echo of \>= 45ml/m2 or LA diameter \>= 50mm OR a HATCH score \>=2 (where 1 point is given for each for hypertension, Age\>75, COPD, and 2 points for each of stroke/TIA, or HF (defined as signs or symptoms of pulmonary edema and may include HFrEF or HFpEF)
- Be considered suitable for both treatment strategies of redo ablation and pacemaker and AV node ablation
- Willingness to participate, complete the QOL questionnaires and ability to sign informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| McGill University Health Center Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.